Categories: legemiddel

  • EU-kommisjonen godkjenner Teysuno for metastatisk kolorektal kreft

    26. januar 2022
    EU-kommisjonen godkjenner Teysuno for metastatisk kolorektal kreft
    Nordic Pharma meddeler at EU-kommisjonen den 24. januar godkjente en ny indikasjon for Teysuno® (tegafur/gimeracil/oteracil) til behandling av pasienter med metastatisk kolorektal kreft der det ikke er mulig å fortsette med en annen fluoropyrimidin-behandling på grunn av spesifikke toksisiteter: hånd-fotsynd

Enter your email address to follow Nordic Drugs

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Nordic Drugs.

Okay